Compare Teladoc Health Inc (TDOC) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teladoc Health Inc vs Twist Bioscience Corp — how do they compare? Teladoc Health Inc trades at $5.54 (market cap $1.01B), while Twist Bioscience Corp trades at $153.4 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 10× Teladoc Health Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Teladoc Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Teladoc Health Inc for 39 Days and Twist Bioscience Corp for 27 Days on average.
| TDOC | TWST | |
|---|---|---|
Market Cap | $1.01B | $10.08B |
Volume | 4,668,477 | 4,229,037 |
Sector | Health | Health |
52-Week High | $9.72 | $205.00 |
52-Week Low | $4.47 | $25.45 |
Typical Hold Time | 39 Days | 27 Days |
Enterprise Value | $1.27B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TDOC trades at $5.56, down 3.64% today, near multi-year lows with a bearish technical outlook. The stock shows mixed fundamentals with revenue stabilizing around $2.5B but persistent net losses, though improving from 2024's $1B loss to $200M in 2025. Valuation metrics appear attractive with P/S of 0.4 and EV/EBITDA of 5.9, while analyst consensus remains cautiously optimistic with a $8.83 price target.
The outlook remains challenged by ongoing losses and BetterHelp segment weakness, but potential exists if Integrated Care profitability improves and new CFO leadership executes effectively. Key risks include sustained negative cash flow, competitive pressures, and the ongoing SEC investigation highlighted in recent news.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
